Links to the ACC.22 late-breaking clinical trials
Here are links to all the American College of Cardiology (ACC) late-breaking clinical studies presented at the 2022 ACC Annual Scientific Session. ACC.22 took place April 2-4, 2022, in Washington, D.C.
These latest practice-changing breakthroughs from top experts will be presented during five late-breaking clinical trial sessions, two late-breaking study deep dive sessions, and three featured clinical research sessions.
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials
Saturday, April 2, 2022
• VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy. Presented by Milind Y. Desai.
• The POISE-3 Trial: Efficacy and Safety of Tranexamic Acid in Patients Undergoing Non-cardiac Surgery. Presented by P.J. Devereaux.
• CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT. Presented by Alan Tita.
Featured Clinical Research I
Saturday, April 2, 2022
• SCORED Trial: Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, and Stroke in the Scored Trial. Presented by Deepak L. Bhatt.
• Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People. Presented by Deepak L. Bhatt.
• COMPLETE: Effects of Complete Revascularization on Angina-related Quality of Life in Patients With St-segment Elevation Myocardial Infarction. Presented by Shamir R. Mehta.
• The FAME 3 Trial: Quality of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery. Presented by William Fuller Fearon.
• Results of the EDIT-CMD Randomized Clinical Trial: Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in Angina and Nonobstructive Coronary Arteries. Presented by Tijn J. Jansen.
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Sunday, April 3, 2022
• TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-high-density Lipoprotein Cholesterol Levels In Statin-treated Patients With Elevated Cholesterol. Presented by Brian Bergmark.
• PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial. Presented by Lorenz Raber.
• APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial. Presented by Steven E. Nissen.
• SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular Risk Reduction. Presented by Dylan L. Steen.
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Sunday, April 3, 2022
• IVVE: Randomized Controlled Trial of Influenza Vaccine in Patients With Heart Failure to Reduce Adverse Vascular Events. Presented by Mark Loeb.
• METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Presented by Gregory D. Lewis.
• PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs With Heart Failure. Presented by Lama Ghazi.
• DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With. Presented by Reduced Ejection Fraction. Presented by Javed Butler.
• Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy. Presented by Florian Rader.
Featured Clinical Research II
Sunday, April 3, 2022
• PACIFIC AF: Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian With Apixaban in Patients With Atrial Fibrillation. Presented by Manesh R. Patel
• NCDR LAAO Registry: Residual Leaks Post Left Atrial Appendage Occlusion. Presented by Mohamad Adnan Alkhouli.
• A Report From the mAFA-II Trial Long-term Extension Cohort: Consumer Smartwatch Screening For Atrial Fibrillation. Presented by Yutao Guo.
• Results From the PARTITA Trial: Catheter Ablation of Ventricular Tachycardia After the First Implantable Cardioverter Shock. Presented by Paolo Della Bella.
• Low Rates of Guideline Directed Care Associated With Higher Mortality in Patients With Infections of Pacemakers and Implantable Cardioverter Defibrillators. Presented by Sean Pokorney.
Late-Breaking Clinical Trials IV
Monday, April 4, 2022
• The PROTECT Trial: Very Mild Peri-operative Hypothermia Versus Aggressive Warming and Myocardial Injury After Non-cardiac Surgery. Presented by Daniel Ira Sessler.
• One-year Results of the CLASP TR Study: Transcatheter Treatment of Tricuspid Regurgitation. Presented by Adam B. Greenbaum.
• Insights From the Corevalve U.S. Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses. Presented by Michael J. Reardon.
• A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement. Presented by Duk-Woo Park.
Late-Breaking Clinical Trials V
Monday, April 4, 2022
• GHATI: Improving STEMI Management Internationally: Two-year Report of 4,015 Patients Enrolled in the American College of Cardiology - Global Heart Attack Treatment Initiative. Presented by Cesar J. Herrera.
• The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis. Presented by Bon Kwon Koo.
• GIPS-IV: The Groningen Intervention Study For the Preservation of Cardiac Function With Sodium Thiosulfate After St-segment Elevation Myocardial Infarction. Presented by Marie-Sophie De Konin.
• BIO|GUARD-MI: The Clinical Effect of Arrhythmia Monitoring After Myocardial Infarction. Presented by Christian Jons.
• Randomized Trial To Confirm The Safety And Effectiveness Of Chocolate Touch Paclitaxel Coated PTA Balloon Catheter In Above The Knee Lesions. Presented by Mehdi H. Shishehbor.
Featured Clinical Research III
Monday, April 4, 2022
• 3-year Efficacy Outcomes From the Spyral HTN-ON Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications. Presented by Felix Mahfoud.
• Fidelity Analyses: Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients With Type 2 Diabetes. Presented by Gerasimos S. Filippatos.
• Secondary Analysis of the CANTOS Trial: Differential Impact of Residual Inflammatory Risk and Residual Cholesterol Risk Among Atherosclerosis Patients With and Without Chronic Kidney Disease. Presented by Paul M. Ridker.
• Trends and Final Results of the North American COVID-19 Myocardial Infarction (NACMI) Registry. Presented by Santiago Garcia.
• Results From the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure. Presented by Mikhail Kosiborod.
Find more on ACC.22, including links to all sessions
Related ACC.22 Coverage:
Salt restrictions, PCI breakthroughs and a social media primer for cardiologists: Day 1 at ACC.22
Cholesterol medications, flu shots and heart failure: Day 2 at ACC.22
TAVR vs. surgery, FFR-guided PCI and DCB safety: Day 3 at ACC.22
VIDEO: TAVR durability outperforms surgical valves — Interview with Michael Reardon, MD
Key Interventional Cardiology Takeaways at ACC 2022
VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98% — interview with Steven E. Nissen, MD.
VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation — Interview with Adam Greenbaum, MD
Cardiology groups debut new heart failure guidelines ahead of ACC.22
Depression linked to a higher stroke risk among heart attack survivors
VIDEO: Lowering mortality rates from infected EP implantable cardiac devices — Interview with Sean Pokorney, MD
VIDEO: Vaccines boosted survival among STEMI patients with COVID-19 — Interview with Santiago Garcia, MD
VIDEO: MitraClip vs. surgical mitral valve replacement — Interview with Joanna Chikwe, MD
VIDEO: American College of Cardiology working to propel cardiovascular innovation
ACC consensus explains what cardiologists should look for in long COVID-19
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com